Hinge Bio
Burlingame, US · Founded 2015 · Delaware corporation · 5 known investors
Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects. Its focus areas include autoimmune and inflammatory diseases, cancer, and other conditions.
Founders & leadership
Hinge Bio was founded in 2015 by Daniel J. Capon, Carin M. Rollins, and Carin Mueller Rollins.
DJ
Daniel J. CaponCo-founder
CM
Carin M. RollinsCo-founder
CM
Carin Mueller RollinsCo-Founder & Chief Operating Officer
HE
Harold E. Selick, PhDExecutive
MS
Miriam SiekevitzExecutive
ML
Malcolm L. GefterNamed on SEC filing
WD
William D. UngerNamed on SEC filing
SS
Samuel SaksNamed on SEC filing
HE
Harold E. "Barry" SelickChief Executive Officer & Director
PB
Paul BrunettaChief Medical Officer
JP
Juha PunnonenChief Development Officer
JC
Joshua CarleChief Business Officer
Investors · 5
Reported raises · per SEC filings
Form D private placements$66.8M disclosed across 3 rounds · 2020–2024
▶$30.6MraisedJan 2025 · 82 investors · BiotechnologyRule 506(b)
▶$30.6MraisedJan 2025 · 82 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John Misha PetkevichDirector
- Alex SilversteinDirector
- Malcolm GefterDirector
- Jeffrey Long-McGieDirector
- Harold E. Selick, PhDExecutive Officer, Director
- Miriam SiekevitzExecutive Officer
- Offering amount
- $40.8M
- Amount sold
- $30.6M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18MraisedFeb 2021 · 77 investors · BiotechnologyRule 506(b)
▶$18MraisedFeb 2021 · 77 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Malcolm GefterDirector
- Miriam SiekevitzExecutive Officer
- William UngerDirector
- John Misha PetkevichDirector
- Daniel CaponExecutive Officer, Director
- Carin RollinsExecutive Officer, Director
- Offering amount
- $18M
- Amount sold
- $18M
- Finders' fees
- $2.1M
- Placement agents
- Arcadia Securities, LLC
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.2MraisedApr 2020 · 100 investors · BiotechnologyRule 506(b)
▶$18.2MraisedApr 2020 · 100 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel J. CaponDirector
- Miriam SiekevitzExecutive Officer
- Malcolm L. GefterDirector
- William D. UngerDirector
- Samuel SaksDirector
- Carin M. RollinsExecutive Officer, Director
- J. Misha PetkevichDirector
- Offering amount
- $19M
- Amount sold
- $18.2M
- Minimum investment
- $1
- Sales commissions
- $833.8K
- Placement agents
- Arcadia Securities, LLC
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Bridgebio20 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Bioworld16 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Hinge Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2018 | $224.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $224.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Hinge Bio do?
- Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects. Its focus areas include autoimmune and inflammatory diseases, cancer, and other conditions.
- Who founded Hinge Bio?
- Hinge Bio was founded by Daniel J. Capon, Carin M. Rollins, Carin Mueller Rollins in 2015.
- Who are Hinge Bio's investors?
- Hinge Bio's investors include Point72, Baruch Future Ventures, InVivium Capital, Agent Capital, Ridgeback Capital.
- How much funding has Hinge Bio raised?
- Hinge Bio has disclosed $66.8M raised across 3 rounds.
- Where is Hinge Bio headquartered?
- Hinge Bio is headquartered in Burlingame, US.